

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)Applicant(s): **Khanna et. al.**

Docket No.

S03284/00/US

Serial No.

09/882,188

AUG 08 2002

Filing Date

06/15/2001

Examiner

Unknown

Group Art Unit

Unknown

Invention: **Cycloalkyl Amino Acids as Integrin Receptor Antag nists****RECEIVED**

AUG 09 2002

TECH CENTER 1600/2900

I hereby certify that this **Suppl. IDS, Form PTO-1449, Copies of References, Fee Transmittal, Postcard**

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Assistant Commissioner for Patents, Washington, D.C. 20231 on

August 5, 2002

(Date)

Linda Haley

(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



| | | | |
|--|--|--------------------------|----------------|
| FEE TRANSMITTAL for FY 2002 <small>Patent fees are subject to annual revision.</small> | | Complete if Known | |
| | | Application Number | 09/882,186 |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27 | | Filing Date | 06/15/2001 |
| | | First Named Inventor | Khanna et. al. |
| | | Examiner Name | Unknown |
| TOTAL AMOUNT OF PAYMENT | | Group Art Unit | Unknown |
| \$180.00 | | Attorney Docket No. | S03284/00/US |

| | | | |
|---|-----------|--|----------|
| METHOD OF PAYMENT (check all that apply) | | FEE CALCULATION (continued) | |
| <input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None | | 3. ADDITIONAL FEES | |
| <input checked="" type="checkbox"/> Deposit Account: | | Large Entity Small Entity | |
| Deposit Account Number | | Fee Code | Fee Code |
| 19-1025 | | 105 130 | 205 65 |
| Deposit Account Name | | Fee Description | |
| Pharmacia Corporation | | Fee Paid | |
| The Commissioner is authorized to: (check all that apply) | | 127 50 227 25 Surcharge - late provisional filing fee or cover sheet | |
| <input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments | | 139 130 139 130 Non - English specification | |
| <input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application | | 147 2,520 147 2,520 For filing a request for ex parte reexamination | |
| <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above identified deposit account. | | 112 920* 112 920* Requesting publication of SIR prior to Examiner action | |
| FEE CALCULATION | | 113 1,840* 113 1,840* Requesting publication of SIR after Examiner action | |
| 1. BASIC FILING FEE | | 115 110 215 55 Extension for reply within first month | |
| Large Entity Small Entity | | 116 400 216 200 Extension for reply within second month | |
| Fee Code | Fee Code | 117 920 217 460 Extension for reply within third month | |
| 101 740 | 201 370 | 118 1,440 218 720 Extension for reply within fourth month | |
| 106 330 | 206 165 | 128 1,960 228 980 Extension for reply within fifth month | |
| 107 510 | 207 255 | 119 320 219 160 Notice of Appeal | |
| 108 740 | 208 370 | 120 320 220 160 Filing a brief in support of an appeal | |
| 114 160 | 214 80 | 121 280 221 140 Request for oral hearing | |
| SUBTOTAL (1) | | 138 1,510 138 1,510 Petition to institute a public use proceeding | |
| | | 140 110 240 55 Petition to revive - unavoidable | |
| 2. EXTRA CLAIM FEES FOR UTILITY AND | | 141 1,280 241 640 Petition to revive - unintentional | |
| Extra Claims Fee from below Fee Paid | | 142 1,280 242 640 Utility issue fee (or reissue) | |
| Total Claims | -20** = 0 | 143 460 243 230 Design issue fee | |
| Independent Claims | -3** = 0 | 144 620 244 310 Plant issue fee | |
| Multiple Dependent | | 122 130 122 130 Petitions to the Commissioner | |
| Large Entity Small Entity | | 123 50 123 50 Processing fee under 37 CFR § 1.17(q) | |
| Fee Code | Fee Code | 126 180 126 180 Submission of Information Disclosure Statement | |
| 103 18 | 203 9 | 581 40 581 40 Recording each patent assignment per property (times number of properties) | |
| 102 84 | 202 42 | 146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a)) | |
| 104 280 | 204 140 | 149 740 249 370 For each additional invention to be examined (37 CFR § 1.129(b)) | |
| 109 84 | 209 42 | 179 740 279 370 Request for Continued Examination (RCE) | |
| 110 18 | 210 9 | 169 900 169 900 Request for expedited examination of a design application | |
| SUBTOTAL (2) | | Other fee (specify) | |
| \$0.00 | | | |
| *or number previously paid, if greater; For Reissues, see above | | SUBTOTAL (3) | |
| | | \$180.00 | |

| | | | |
|---------------------|--------------------------|-----------------------------------|----------------|
| SUBMITTED BY | | Complete (if applicable) | |
| Name (Print/Type) | Rachel A. Polster | Registration No. (Attorney/Agent) | 47,004 |
| Signature | <i>Rachel A. Polster</i> | Telephone | 6-314-694-7354 |
| | | Date | Aug. 2, 2002 |

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



7
8/13/02
89

Case S03284/00/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

KHANNA ET AL

SERIAL NO: 09/882,186 ✓

FILED: June 15, 2001 ✓

GROUP ART UNIT: Unknown

EXAMINER: Unknown

DATE: August 5, 2002

TITLE: CYCLOALKYL ALKANOIC ACIDS AS INTEGRIN RECEPTOR
ANTAGONISTS ✓

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

These newly cited documents are as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

08/09/2002 SSESHE1 00000076 191025 09882186
01 FC:126 180.00 CH

Rachel A. Polster
Attorney for Applicants
Registration No. 47,004
(314) 694-7354 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
800 North Lindbergh Boulevard, 04E
St. Louis, MO 63167

TECH CENTER 1600/2900

AUG 09 2002

RECEIVED